UHCC Hawaii Minority Health and Cancer Disparities

SPORE – 2023-2024


For this recently funded Cancer Health Disparity SPORE planning grant, applications are requested that address cancer-related minority health or disparities research with translational endpoints. Each proposed project must meet the NCI definition of translational research, and cancer health disparities or minority health research (PAR-23-284) (see below). The translational nature of the projects proposed may pertain to advancing any clinically relevant cancer area, including cancer early detection, prevention, diagnosis, treatment and/or survivorship.

The proposed project needs to address cancer minority health or disparities, have clear translational potential, and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches (see PAR-23-284). Projects proposing mainly studies in non-human models are allowed only if a human application/human endpoint is clearly delineated and would be the next step in the research. Finally, proposals to develop new cancer-relevant interventions should include both a laboratory component addressing mechanisms and a human application that must be proposed within the project aims. These grants are funded by the Hawaii Minority Health and Cancer Disparities SPORE (P20 CA275734). Up to two 1-year grants will be awarded in this cycle, with budgets of up to $50,000 each.

Evaluation Criteria

The criteria that will be evaluated for funding are the following:

  • Scientific merit and potential impact
  • Innovation and significance of the question being studied
  • Translational potential
  • Relevance to cancer minority health or disparities
  • Potential as a future SPORE project
  • Applications are particularly encouraged from early-stage investigators


  • Cancer Researchers who are UH Faculty and/or UHCC members at all levels (Full, Associate, Affiliate, Collaborating, and Clinical)
  • New project that is not supported by existing extramural funding
  • Applicant has not received SPORE seed funding during the last 2 years
  • A one-page progress report is required at the end of the project period

Other useful information can be found in the SPORE PAR:

PAR-23-284: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) (nih.gov)

For more information please see attached flyer.


Written by